Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nauheim – page 108

1 333 clinical trials in Bad Nauheim, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nauheim at a glance
1 333
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 333 trials in Bad Nauheim

Open in trial search

Study of RO7247669 and Nab-Paclitaxel vs. Pembrolizumab and Nab-Paclitaxel for Patients with Untreated, PD-L1 Positive, Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Food allergy

Not recruiting

Study on Long-Term Safety of Ligelizumab for Patients with Food Allergies

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Epinephrine
  • Sponsor:Novartis Pharma AG

Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-501A
  • Sponsor:Allogene Therapeutics Inc.

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Alopecia areata

Not recruiting

Study on Baricitinib for Treating Children Aged 6 to 17 with Alopecia Areata

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Bronchiectasis

Not recruiting

Study on Long-Term Safety and Efficacy of BI 1291583 in Patients with Bronchiectasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Status epilepticus

Not recruiting

Study on Ganaxolone for Patients with Refractory Status Epilepticus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ganaxolone
  • Sponsor:Marinus Pharmaceuticals Inc.

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study of Asciminib Treatment for Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Oncolytics Biotech Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nauheim

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on hypertrophic cardiomyopathy treatments, including trials of mavacamten and aficamten. Research also covers advanced therapies for heart failure and pulmonary hypertension management.

  • Cardiac Structure Improvement
  • Heart Function Enhancement
  • Pulmonary Hypertension Treatment

Long-term safety and efficacy evaluations of novel cardiovascular medications are prioritized.

02 Oncology Studies

Advanced research in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate innovative combination therapies including atezolizumab and targeted treatments.

  • Neoadjuvant Therapies
  • Immunotherapy Applications
  • Treatment Resistance

Emphasis on improving survival rates and reducing recurrence in early-stage breast cancer.

03 Inflammatory Conditions

Clinical investigations of inflammatory diseases including myositis and arteritis. Studies evaluate new biological treatments and their long-term effectiveness in managing chronic inflammatory conditions.

  • Autoimmune Disorders
  • Novel Biologics
  • Disease Modification

Focus on developing targeted therapies for better disease control and improved patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.